Most Read Articles
Roshini Claire Anthony, 09 Dec 2020

Adherence to lipid-lowering medications (LLMs) prior and following cancer diagnosis may have bearing on cancer-specific mortality, according to a study from Australia.

Jairia Dela Cruz, 15 Dec 2020
Initiating statin therapy immediately after onset of large vessel occlusion in acute ischaemic stroke patients proves beneficial, leading to better functional outcome and lower mortality at 90 days, according to data from the RESCUE*‐Japan Registry 2.
Pearl Toh, 26 Jan 2021
While children with inflammatory bowel disease (IBD) see their conditions improve with biologic therapy, those with ulcerative colitis (UC) tend to have residual disease activity even after clinical remission, according to two separate studies presented at the 2021 Crohn’s and Colitis Congress.

Second-line avelumab shows therapeutic potential in advanced HCC

21 Feb 2021

Use of the antiprogrammed death ligand 1 (PD-L1) antibody avelumab in the second-line treatment of patients with advanced hepatocellular carcinoma (HCC) yields moderate efficacy with tolerable safety profile, according to the results of a phase II trial.

In total, 30 patients (median age, 62 years; 73.3 percent male) with Child-Pugh A score who had at least one measurable lesion received intravenous avelumab 10 mg/kg every 2 weeks until disease progression or unacceptable toxicity.

Chronic HBV infection was the most common aetiology of HCC (n=26; 86.7 percent), followed by chronic HCV infection (n=3; 10.0 percent) and alcoholic liver disease (n=1; 3.3 percent). The most frequent sites of metastasis were liver (76.7 percent), lung (63.3 percent), lymph node (40.0 percent), and bone (13.3 percent). All 30 patients had prior treatment with sorafenib.

Over a median follow-up of 13.9 months, 27 progression events and 20 deaths occurred. Three patients (10.0 percent) achieved partial responses, 19 (63.3 percent) had stable disease, and none showed complete response.

Objective response rate was 10.0 percent, while disease control rate was 73.3 percent. The median time to progression (TTP) and overall survival (OS) were 4.4 and 14.2 months, respectively. PD-L1 expression did not modify avelumab response.

Prior duration of sorafenib treatment, when dichotomized by the median 2.7 months, was associated with treatment outcome, such that patients with longer sorafenib duration had longer TTP (6.5 vs 1.8 months; p=0.007) and OS (19.0 vs 7.8 months; p=0.006) with avelumab.

The study drug was well tolerated. There were seven cases of grade 3 adverse events, and none of the patients developed grade 4 events.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 09 Dec 2020

Adherence to lipid-lowering medications (LLMs) prior and following cancer diagnosis may have bearing on cancer-specific mortality, according to a study from Australia.

Jairia Dela Cruz, 15 Dec 2020
Initiating statin therapy immediately after onset of large vessel occlusion in acute ischaemic stroke patients proves beneficial, leading to better functional outcome and lower mortality at 90 days, according to data from the RESCUE*‐Japan Registry 2.
Pearl Toh, 26 Jan 2021
While children with inflammatory bowel disease (IBD) see their conditions improve with biologic therapy, those with ulcerative colitis (UC) tend to have residual disease activity even after clinical remission, according to two separate studies presented at the 2021 Crohn’s and Colitis Congress.